Media Advisory: GenSpera's G-202 HCC Clinical Trial
Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation from 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Me...
Date : 07/22/2014 @ 8:00AM
Source : PR Newswire (US)
Stock : Genspera (QB) (GNSZ)
Quote : 0.88 -0.007 (-0.79%) @ 10:17AM
Media Advisory: GenSpera's G-202 HCC Clinical Trial Presentation from 5th Asia-Pacific Primary Liver Cancer Expert (APPLE) Me...
Print
Alert
Genspera (QB) (USOTC:GNSZ)
Intraday Stock Chart
Today : Tuesday 22 July 2014
Click Here for more Genspera (QB) Charts.
SAN ANTONIO, July 22, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE) presentation of the G-202 hepatocellular carcinoma (HCC) clinical trial data is now available for download for media and investors.
On July 12th Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in HCC patients, presented the HCC clinical trial update for G-202, in Taipei, Taiwan.
HCC is the sixth most common malignancy worldwide. It is the fifth most common malignant disease in men and the eighth most common in women. It is the third most common cause of death from cancer, after lung and stomach cancer.*
Dr. Craig Dionne, GenSpera CEO, recently said of its lead drug candidate G-202, based on the new data presented, "These positive results enable management to remain optimistic about our ambitious G-202 clinical development program which is expanding into glioblastoma, prostate cancer and renal cell carcinoma trials. Although still in early stages, we believe this clinical strategy will continue to build significant value in G-202 and in the company. We are particularly excited by the potential that G-202 is showing as a treatment for patients with liver cancer, a market which is expected to be at $1.5 billion by 2019."
Presentation
"Clinical Activity of G-202, a Thapsigargin-Based Prostate Specific Membrane Antigen (PSMA)-Activated Prodrug in Patients with Progressive Hepatocellular Carcinoma (HCC)"
Media and investors can view Dr. Mahalingam's presentation at: http://www.genspera.com/press/140712_APPLE201..._FINAL.pdf
About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.
G-202 Phase II clinical trials are underway in hepatocellular carcinoma, glioblastoma and prostate cancer patients.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
*Source: http://www.worldgastroenterology.org/assets/d...oma_en.pdf
About APPLE 2014
The Asia-Pacific Primary Liver Cancer Expert Association (APPLE) Congress was held July 11 – 13, 2014, at the Grand Hotel Taipei in Taipei, Taiwan. APPLE 2014 is hosted by the Chinese Oncology Society of Taiwan and co-hosted by the Taiwan Association for the Study of the Liver, the Gastroenterological Society of Taiwan, and the Taiwan Liver Cancer Association. APPLE is an international platform for HCC that brings together scientific experts from across the world to discuss curative treatment, systemic and anti-viral therapies, HCC pathology and social perspectives as well. http://www.2014applecongress.org.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
CONTACT:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Investors:
Steve Gersten
Capital Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920
Media:
D. Van Zant
800-665-0411
SOURCE GenSpera, Inc.
Copyright 2014 PR Newswire
Rebus Hldgs (RBSH) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A New Landmark in Midland Midland, Texas just got itself a fresh, shiny addition in the form of a real estate deal worth $32.5 million. On the books as of September 1, 2026, 3700 Midway, LLC has grabbed hold of Midway Station, setting their stakes straight in the heart of Midland's bustling business corridor. The Scope of the Deal This acquisition is more than just a line...
Continue Reading
USB's Data-Driven Approach Transforms Banking Remember the days of handing out toasters to keep customers? Union Savings Bank (USB) sure doesn't seem to, as it embraces tech-savvy methods to keep its clientele content. Instead, the $3.3 billion community bank based in Danbury, Connecticut, has deployed NGDATA's AI Hub, transforming its approach to reducing customer churn...
Continue Reading
Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...
Continue Reading
Qingdao and Yerevan: More Than Just a Port of Call Who would have thought? An Armenian ambassador talking shop in a Chinese port city isn't your everyday headline, but let me tell you, it's big news if you're watching global growth. Armenian Ambassador Vahe Gevorgyan's recent spiel in Qingdao might not turn heads on Wall Street, but there's more under the hood than meets...
Continue Reading
Manulife: Debuting $750M in Subordinated Notes When it comes to Manulife's latest move, it's all about the numbers. They've priced a U.S. public offering of a meaty $750 million in subordinated notes at an enticing 6.146% interest rate. That's no pocket change, folks, and it highlights a strategy or a gamble, depending on your view. But here's the kicker: these notes may...
Continue Reading
Imagine a cancer struggle fueling creativity – a hopeful story from the racetrack lights up this reality as Valvoline and a young survivor rev up their engines for children with blood cancer. Powerful Partnership Takes Unforgettable Turn Palmer Goforth, a twelve-year-old cancer survivor, never imagined his hobby of drawing sketches would lead to designing a NASCAR car....
Continue Reading
Hold onto your hats, folks, because the American Diabetes Association (ADA) just dropped a bombshell report with findings that'll make your head spin if you're keyed into the healthcare sector. They’ve wrapped this up in a bow of accountability, but let's dig into the crux of it. Behind the Controversy: The New Orleans Incident This all harks back to an incident on June...
Continue Reading
A Public Campaign for Recovery Awareness Anyone with a pulse on what's going on in the addiction recovery landscape knows the significance of events like Recovery Happens. It's not just another day in Sacramento; it's a rallying cry for change—a public affirmation that recovery is tangible and thriving. This isn't about showy gala dinners or fancy corporate events; it's...
Continue Reading
Navigating Uncharted Waters with New Vessels Some days, you see a giant leap in an industry and think, "Well, someone's got ambition." Here, we're talking about ZPMC's gutsy naming ceremony for two spanking new 38,000 DWT multipurpose heavy-lift ships destined for Chipolbrok, happening fresh off the docks in Shanghai. Specifications That Make Waves Imagine a vessel the...
Continue Reading
Pioneering Sovereign Robotic Warfare The defense sector's landscape is shifting, and Aitan is driving a movement with their 'Robotic Sovereignty-as-a-Service'. Coming out of stealth with a hefty $41 million funding boost, this Israeli-American company is redefining modern warfare's playbook. In today's unpredictable world, traditional combat methods are becoming relics of...
Continue Reading
Top 5 Most Recently Viewed Articles
Exhibitus Launches EXstudios for Enhanced Engagement Exhibitus has introduced EXstudios, an innovative experiential strategy and creative ideation studio aimed at expanding the company's existing capabilities. This new division places a strong emphasis on experiential storytelling and front-end strategy across various marketing channels. For over three decades, Exhibitus...
Continue Reading
Overview of the Milk Ingredients Market The global milk ingredients market is witnessing a remarkable expansion, with projections indicating an increase to USD 74.7 billion by the end of the year. The compound annual growth rate (CAGR) of 4.9% is anticipated between the current year and 2034. By the conclusion of this period, the market is expected to reach approximately...
Continue Reading
Klear.ai Teams Up with APRA for Claims Modernization Klear.ai, a pioneer in intelligence-powered claims and risk solutions, is embarking on a transformative journey alongside the Alaska Public Risk Alliance (APRA). This collaboration is focused on modernizing and unifying claims operations as APRA prepares to consolidate public risk pools, moving away from the separate...
Continue Reading
DraftKings (NASDAQ: DKNG): Promising Investment Insights DraftKings is a leading digital sports betting and iGaming app provider that has experienced significant growth in recent years, although it still faces challenges in achieving profitability. The company has captured a substantial share of the online betting market in partnership with their competitor, suggesting...
Continue Reading
Understanding Baxter International Inc.'s Legal Landscape Baxter International Inc. (NYSE: BAX) has become a focal point for investors concerned about the integrity of its communications during a recent class action lawsuit. The Rosen Law Firm, known for advocating investor rights, is currently rallying stock purchasers of Baxter who acquired shares between specific...
Continue Reading